Monotherapy With P2Y12 Inhibitors in Patients With Atrial fIbrillation Undergoing Drug-eluting Stent Implantation
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 3010 participants.
Also called NCT05955365
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 3,010 participants
- Registry
-
NCT05955365
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Belgium, France, Germany, Italy, Netherlands, Poland, Spain, Switzerland, United Kingdom
- Registry status
- Recruiting
Technical summary
Registry record NCT05955365. Randomized; no masking; primary purpose treatment. Start 2023-12-18 (actual); primary completion 2027-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Monotherapy With P2Y12 Inhibitors in Patients With Atrial fIbrillation Undergoing Drug-eluting Stent Implantation
- Acronym
- MATRIX-2
- Condition
- Atrial Fibrillation (AF)
- Condition
- Oral Anticoagulation
- Condition
- P2Y12 Inhibitor
- Intervention (Drug)
- P2Y12 inhibitor
- Intervention (Drug)
- Aspirin
- Intervention (Drug)
- DOAC
- Lead sponsor
- Insel Gruppe AG, University Hospital Bern
- Collaborator
- Sahajanand Medical Technologies Limited
Record details
- Record id
cardio:ct-nct05955365- Content hash
cf1873d63c2b9ad411f5ed54aed5103f9a1b1d721ee635e43f5ce098c35767ca